TY - JOUR
T1 - Synergistic effect of arsenic trioxide and Flt3 inhibition on cells with Flt3 internal tandem duplication
AU - Takahashi, Shinichiro
AU - Harigae, Hideo
AU - Yokoyama, Hisayuki
AU - Ishikawa, Izumi
AU - Abe, Shouri
AU - Imaizumi, Masue
AU - Sasaki, Takeshi
AU - Kaku, Mitsuo
N1 - Funding Information:
This work was supported in part by the Tohoku University Hospital Clinical Research Promotion Program for Young Scientists (S.T.), the Kurozumi Medical Foundation (S.T.), the Takeda Science Foundation (S.T.), the Kanae Foundation for Life & Socio-medical Science (S.T.), the Life Science Founda- tion of Japan (S.T.), and MEXT.KAKENHI (17790635) (S.T.). We thank Ms. M. Watanabe for excellent technical assistance.
PY - 2006/10
Y1 - 2006/10
N2 - Flt3 internal tandem duplication (Flt3-ITD) is a prevalent mutation in acute myeloid leukemia (AML). Flt3-ITD constitutively activates various signaling pathways, including a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway. Arsenic trioxide (ATO) and MEK inhibition were recently reported to interact synergistically to induce apoptosis in AML cells. In this study, we aimed to clarify whether ATO and Flt3 inhibition would be a more specific and efficient therapy for Flt3-ITD cells. We demonstrate that the combination of ATO and an Flt3 inhibitor, AG12%, profoundly inhibits the growth of Flt3-ITD cells and induces their apoptosis. We further revealed that this combined treatment potently inhibits the ERK activity that might be responsible for cell growth. Moreover, using the Chou-Talalay method, we observed a synergistic growth-inhibitory effect for ATO and AG12% in Flt3-ITD cells (BaF3-Flt3-ITD, MV4-11, and PL-21 cells), but not in Flt3 wild-type cells (RS4-11 and NB4 cells), for almost all dose ranges tested. Our results provide an experimental basis for a specific and efficient therapy for Flt3-ITD cells that involves combined treatment with Flt3 inhibitors and ATO.
AB - Flt3 internal tandem duplication (Flt3-ITD) is a prevalent mutation in acute myeloid leukemia (AML). Flt3-ITD constitutively activates various signaling pathways, including a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway. Arsenic trioxide (ATO) and MEK inhibition were recently reported to interact synergistically to induce apoptosis in AML cells. In this study, we aimed to clarify whether ATO and Flt3 inhibition would be a more specific and efficient therapy for Flt3-ITD cells. We demonstrate that the combination of ATO and an Flt3 inhibitor, AG12%, profoundly inhibits the growth of Flt3-ITD cells and induces their apoptosis. We further revealed that this combined treatment potently inhibits the ERK activity that might be responsible for cell growth. Moreover, using the Chou-Talalay method, we observed a synergistic growth-inhibitory effect for ATO and AG12% in Flt3-ITD cells (BaF3-Flt3-ITD, MV4-11, and PL-21 cells), but not in Flt3 wild-type cells (RS4-11 and NB4 cells), for almost all dose ranges tested. Our results provide an experimental basis for a specific and efficient therapy for Flt3-ITD cells that involves combined treatment with Flt3 inhibitors and ATO.
KW - AG1296
KW - AML
KW - ATO
KW - Flt3-ITD
KW - Synergism
UR - http://www.scopus.com/inward/record.url?scp=33750314586&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750314586&partnerID=8YFLogxK
U2 - 10.1532/IJH97.06076
DO - 10.1532/IJH97.06076
M3 - Article
C2 - 17050201
AN - SCOPUS:33750314586
SN - 0925-5710
VL - 84
SP - 256
EP - 261
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 3
ER -